Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

This phase II trial studies how well pembrolizumab works in treating patients with small bowel adenocarcinoma that has spread to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT Number	NCT02949219
Lead Sponsor	Academic and Community Cancer Research United Collaborators: National Cancer Institute (NCI)
Conditions	Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma
Enrollment	41 participants
Start Date	2017-03-24
Primary Completion	2019-01-31 (estimated)
Study Completion	2024-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-22